| Issue Date | Title | Author(s) |
| 2019-02-26 | HMGA2 promotes long-term engraftment and myeloerythroid differentiation of human hematopoietic stem and progenitor cells | Kumar, P; Beck, D; Galeev, R; Thoms, JAI; Talkhoncheh, MS; de Jong, I; Unnikrishnan, A; Baudet, A; Subramaniam, A; Pimanda, JE; Larsson, J |
| 2018-06-01 | Effect of glycated insulin on the blood-brain barrier permeability: An in vitro study | Shahriyary, L; Riazi, G; Lornejad, MR; Ghezlou, M; Bigdeli, B; Delavari, B; Mamashli, F; Abbasi, S; Davoodi, J; Saboury, AA |
| 2015-11-16 | Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Promotes Angiogenesis and Ischemia-Induced Neovascularization Via NADPH Oxidase 4 (NOX4) and Nitric Oxide-Dependent Mechanisms. | Di Bartolo, BA; Cartland, SP; Prado-Lourenco, L; Griffith, TS; Gentile, C; Ravindran, J; Azahri, NSM; Thai, T; Yeung, AWS; Thomas, SR; Kavurma, MM |
| 2021-03-03 | A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma | Cheung, BB; Kleynhans, A; Mittra, R; Kim, PY; Holien, JK; Nagy, Z; Ciampa, OC; Seneviratne, JA; Mayoh, C; Raipuria, M; Gadde, S; Massudi, H; Wong, IPL; Tan, O; Gong, A; Suryano, A; Diakiw, SM; Liu, B; Arndt, GM; Liu, T; Kumar, N; Sangfelt, O; Zhu, S; Norris, MD; Haber, M; Carter, DR; Parker, MW; Marshall, GM |
| 2018-08 | MASTL overexpression promotes chromosome instability and metastasis in breast cancer. | Rogers, S; McCloy, RA; Parker, BL; Gallego-Ortega, D; Law, AMK; Chin, VT; Conway, JRW; Fey, D; Millar, EKA; O'Toole, S; Deng, N; Swarbrick, A; Chastain, PD; Cesare, AJ; Timpson, P; Caldon, CE; Croucher, DR; James, DE; Watkins, DN; Burgess, A |
| 2017-04-18 | Clinical relevance of the transcriptional signature regulated by CDC42 in colorectal cancer. | Valdés-Mora, F; Locke, WJ; Bandrés, E; Gallego-Ortega, D; Cejas, P; García-Cabezas, MA; Colino-Sanguino, Y; Feliú, J; Del Pulgar, TG; Lacal, JC |
| 2017-04-05 | Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. | Vennin, C; Chin, VT; Warren, SC; Lucas, MC; Herrmann, D; Magenau, A; Melenec, P; Walters, SN; Del Monte-Nieto, G; Conway, JRW; Nobis, M; Allam, AH; McCloy, RA; Currey, N; Pinese, M; Boulghourjian, A; Zaratzian, A; Adam, AAS; Heu, C; Nagrial, AM; Chou, A; Steinmann, A; Drury, A; Froio, D; Giry-Laterriere, M; Harris, NLE; Phan, T; Jain, R; Weninger, W; McGhee, EJ; Whan, R; Johns, AL; Samra, JS; Chantrill, L; Gill, AJ; Kohonen-Corish, M; Harvey, RP; Biankin, AV; Australian Pancreatic Cancer Genome Initiative (APGI),; Evans, TRJ; Anderson, KI; Grey, ST; Ormandy, CJ; Gallego-Ortega, D; Wang, Y; Samuel, MS; Sansom, OJ; Burgess, A; Cox, TR; Morton, JP; Pajic, M; Timpson, P |
| 2016-09-13 | Short term ex-vivo expansion of circulating head and neck tumour cells. | Kulasinghe, A; Perry, C; Warkiani, ME; Blick, T; Davies, A; O'Byrne, K; Thompson, EW; Nelson, CC; Vela, I; Punyadeera, C |
| 2016-08-09 | A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner. | Sutton, SK; Carter, DR; Kim, P; Tan, O; Arndt, GM; Zhang, XD; Baell, J; Noll, BD; Wang, S; Kumar, N; McArthur, GA; Cheung, BB; Marshall, GM |
| 2016-08-09 | A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner. | Sutton, SK; Carter, DR; Kim, P; Tan, O; Arndt, GM; Zhang, XD; Baell, J; Noll, BD; Wang, S; Kumar, N; McArthur, GA; Cheung, BB; Marshall, GM |
